Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Company Profile
- CEO
- David Palach
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Employees
- 8
- Beta
- 1.86
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.31
Financials
Revenue
$0.00-100.0%Net Income
$-11.14MEBITDA
$-1.47MFree Cash Flow
$-592.1KEPS (diluted)
$-13.66Shares Outstanding (diluted)
816.1K+224730.9%Operating Expenses
$1.47MCash & Debt
$8.88MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-4.00M | $-24.78 |
| 2024 | $210.0K | $-5.19M | $-31.09 |
| 2023 | $263.4K | $-6.52M | $-190.14 |
| 2022 | $394.0K | $-5.74M | $-401.97 |
| 2021 | $438.1K | $-4.82M | $-504.05 |
| 2020 | $232.3K | $-1.59M | $-256.94 |
| 2019 | $175.8K | $-1.97M | $-339.19 |
| 2018 | $426.6K | $-356.9K | $-91.84 |
| 2017 | $343.9K | $-672.1K | $-742.94 |
| 2016 | $322.0K | $-599.5K | $-1697.85 |
| 2013 | $522.1K | $-468.8K | $-1543.50 |
| 2012 | $351.4K | $-695.7K | $-2058.00 |
| 2011 | $460.1K | $-606.9K | $-1800.75 |
| 2010 | $274.0K | $-629.0K | $-2315.25 |
Valuation
NXTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
View source ↗ - Newsglobenewswire.com·13d ago·Negative
…areX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that Prof.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX's future in-vitro drug discovery programs
View source ↗
Earnings
Wed, Dec 2(in 8 weeks)
Estimates and results for NXTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NXTS officers and directors.
- Bought
- —
- Sold
- $172
0 trades
1 trade
- Lee Eun Youngsold
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NXTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.